Technetium-99m Sestamibi Tumor Imaging:

Technetium-99m Sestamibi Tumor Imaging:

Technetium 99m Sestamibi Tumor Imaging General Considerations:

The accumulation of Tc-Sestamibi (Tc-MIBI) in tumors is likely related to a number of variables. Tc-MIBI is a lipophilic monovalent cation (an isonitrile compound). It enters the cell via passive diffusion across plasma and mitochondrial membranes. It is postulated that Tc-MIBI accumulates within the mitochondria and cytoplasm of cells on the basis of electrical potentials generated across the membrane bilayers. At equilibrium it is sequestered largely within mitochondria by a large negative transmembrane potential. The agent is fixed intracellularly as long as cell membrane integrity is intact and nutrient blood flow persists.

Washout of Tc-MIBI from tumor cells is related to the energy (ATP) dependent transmembrane transporter proteins which include the P-glycoprotein pump system (P-gp) and the multidrug resistance protein (MRP) [7,8,38]. Tumor cells with a higher concentration of these transmembrane proteins demonstrate a faster rate of Tc-MIBI clearance (and hence, less tracer uptake) [7,8,22]. MIBI tumor washout can aid in identification of multi-drug resistant tumors and may provide prognostic information [38]. P-gp is also highly expressed at the lumenal endothelium of the human blood-brain barrier and this prevents entry of many CNS-active drugs [49]. P-gp inhibitors such as tariquidar have been developed as an adjunct for drug-resistant tumors and may also aid in increasing brain penetration of CNS medications [49].

There are many advantages to using Technetium rather than Thallium for scintigraphic imaging. Technetium's shorter physical half-life permits the use of a higher dose of the radiopharmaceutical [37]. This translates to a higher count rate which will shorten imaging times and provide sharper pictures [37]. The gamma energy of Technetium (140 keV) is optimal for use with the detector crystal used in the gamma camera and will undergo less attenuation and scatter. Technetium is also readily available and produced daily from a Molybdenum generator in most Nuclear Medicine departments. Since its introduction, Tc-99m-Sestamibi has been shown to be of value in the evaluation of many tumors.

Bone and Soft Tissue Tumors:

Tc-MIBI has been evaluated for distinguishing benign from malignant bone lesions [22]. Sensitivity has been reported to be 81%, and specificity 87%. Tc-MIBI may be particularly useful in evaluating sites of fracture- pathologic fractures demonstrate increased Tc-MIBI accumulation, while non-pathologic fractures do not [22]. False positive findings can be seen in myositis ossificans, osteoid osteomas, non-ossifying fibromas, and giant cell tumors [22].

Tc-MIBI has also been used in assessing malignant bone and soft tissue tumor response to therapy [28]. Like thallium, uptake is non-specific and can be seen in both benign and malignant lesions. Tc-MIBI permits the acquisition of flow images which are not possible with Thallium. [16]

Despite improved clinical outcome in osteosarcomas patients through the use of multiagent chemotherapy regimens, systemic relapses occur in about 50% of cases [38]. Conventional cytotoxic agents such as doxorubicin used in the treatment of osteosarcoma are substrates of multidrug resistance proteins which can limit the agents effectiveness [38]. Following Tc-MIBI injection, measurement of tumor to background activity at 10 and 60 minutes post injection can be used to determine the percent washout of the agent [38]. A higher washout indicates multidrug resistance protein expression by the tumor and a higher likelihood that the tumor will not have a complete response to therapy [38].

CNS Neoplasms:

Tc-Sestamibi can be used to confirm CNS malignancy and can be particularly useful in differentiating neoplastic from non-neoplastic intracranial hemorrhage (ICH) [42]. Scans performed within 5 days of the event (and preferably within 2 days) will show tracer uptake in neoplastic ICH, but no tracer accumulation in nonneoplastic ICH [42]. If imaging is delayed, Tc-MIBI uptake can also be seen in non-neoplastic ICH- so early post-event imaging is critical [42]. Unfortunately, choroid plexus activity seen with Tc-sestamibi limits its usefulness for CNS neoplasm imaging [15] and choroid plexus uptake is not blocked by the use of perchlorate. In a comparison of Tc-MIBI with FDG PET for the detection of recurrent CNS neoplasm, Tc-MIBI was found to be of limited value [40].

Tc-Sestamibi has also been used to evaluate CNS neoplasms response to therapy. Tc-MIBI uptake is a marker of mitochondrial oxidative capacity. Tc-MIBI uptake correlates with the mitochondrial marker malate dehydrogenase. The addition of the mitochondrial uncoupler CCCP (which contains cyanide) can release 85% of the Tc-MIBI. In patients responding to chemotherapy, Tc-MIBI uptake within the lesion frequently decreases and this is felt to be reflective of damage to the mitochondrial oxidative capacity of the tumor.

Breast Cancer:

For the evaluation of focal breast lesions:

Mammography is the method of choice for the early detection of clinically occult breast cancer [25]. A 30% reduction in mortality has been reported among women enrolled in mammographic screening programs [25]. Screening mammography has a relatively high sensitivity of nearly 90%, but is limited by its lack of specificity which is only about 35-54%, even in specialized centers [23,25]. The utility of mammography is especially limited in patients with large amounts of glandular tissue and dense breasts [25].

Tc-sestamibi (Tc-MIBI) has been used to evaluate breast lesions. Tc-sestamibi binds to mitochondrial cells and increases in mitochondrial density typically denote cellular proliferation [59]. Because cancer cells have higher proliferation, they will demonstrate an increase in tracer uptake compared to the surrounding tissue [59]. However, uptake and retention of tracer in breast cancers appears to depend on several factors such as regional blood flow, increased mitochondrial concentration in cancer cells, increased angiogenesis, and tissue metabolism [46,56]. Unlike mammography, the Tc-sestamibi examination is not affected by breast density [6,32]. Background uptake of Tc-sestamibi can be greater in the luteal phase of the menstrual cycle and in postmenopausal women using hormone replacement therapy and tends to be greater in dense breasts [54].

Breast specific gamma imaging systems have been developed and have improved detection of small breast lesions compared to conventional gamma cameras [55]. Dual head CZT solid state breast imaging systems are the state of the art for molecular breast imaging [55]. Previously, the typical dose was approximately 20-30 mCi of Tc-Sestamibi, but a dose as low as 7 to 10 mCi can be used for high-resolution breast-specific CZT cameras [50,52,55]. Specially designed dual head CZT imaging systems with slight breast compression have been developed to permit optimal imaging of the breasts [52]. The dual head design permits increases sensitivity (90% vs 80% with single detector system) and also increases detection of sub-centimeter tumors compared to single headed camera systems [52,53]. The increased sensitivity is due to decreased distance between the detector and the lesion [53]. Standard CC and MLO projection images of each breast should be acquired [55]. High resolution planar images are acquired for 7 to 10 minutes per view (or 100,000 counts [53]) [52,55]. The exam lasts approximately 40-45 minutes [53].

Studies have demonstrated that if patients are in a fasting (3 hours), resting, and a warm state the uptake of Tc-sestamibi in breast tissue is improved [55]. In pre-menopausal women, MIBI imaging is best performed during the follicular phase of the menstrual cycle, between days 2 and 12, when fibroglandular breast tissue is not as physiologically active and should have lower sestamibi accumulation [57,60]. Early imaging is more sensitive than delayed studies as sestamibi accumulation within breast lesions decreases significantly by one hour after tracer administration [34,36]. Optimum imaging should begin within 5 to 10 minutes after tracer injection [36,55]. There may be adherence of tracer in the regional veins after injection making evaluation of the axilla and upper breast suboptimal- the arm opposite the side of the lesion or the foot should therefore be injected. High-resolution breast-specific gamma cameras provide a smaller organ-to-detector distance and the ability to detect subcentimeter lesions [50]. Lesions as small as 4 mm can be detected when using breast specific, high-resolution gamma imaging systems [23,45]. When combined with conventional mammography the two exams have an overall improved sensitivity for malignancy [21].

Overall, Tc-Sestamibi has a sensitivity of 70-96% and a specificity of 60-100% for determination of breast malignancy [6,19,21,23,25,31,32,34,51,59] (the higher sensitivities are associated with the use of high-resolution breast-specific gamma cameras [50]). The overall sensitivity is not affected by breast density [50,51]. The reported sensitivities are similar to that reported for FDG PET imaging (although FDG images usually demonstrate a greater tumor to normal tissue activity ratio) [19]. The negative predictive value has been reported to be between 81-97%. A comprehensive review of the literature found a total average sensitivity of 84.5%, average specificity of 89%, average positive predictive value of 89%, average negative predictive value of 84%, and an average accuracy of 86% [24]. Most false negative exams occur with lesions smaller than 1 to 1.5 cm in size or non-palpable lesions [21,32,35]. Studies indicate that the exams sensitivity drops to 51% to 72% for non-palpable lesions [2,3,6,20] (and the lower sensitivity is probably more accurate [6]). A recent multicenter prospective trial [20] found an overall institutional sensitivity of 75.4%, a specificity of 82%, a positive predictive value of 74.5%, and a negative predictive value of 83.4% (with a disease prevalence of 40%). In this same study, the sensitivity for tumors under 1 cm in size was only 48.2% [20]. In another study, sensitivity for tumors less than 1 cm was 55.6% [51]. In the European multicenter study, the sensitivity was 71% and the specificity was 69% [41].

Large lesions may also go undetected [21]. In one study, 19% of false-negative exams occurred in lesions over 3 cm in size [31]. Negative exams in large lesions may be related to: 1- overexpression of the multidrug resistance gene; 2- lesions with low desmoplastic activity or low cellular proliferation; and 3- lesions with low cell counts, low vascularity, and absence of inflammation [31,41]. Detection of smaller lesions and sensitivity is improved with the use of a high-resolution breast specific gamma camera, but the equipment costs make such a unit impractical for routine clinical use [35,44,47].

False positive exams have been described with lymph nodes, fibroadenomas, papillomas, epithelial hyperplasia, mastitis, fat necrosis, scleradenosis, and fibrocystic breast disease [1,11,31,57]. Patients with fibrocystic disease are more likely to have false-positive examinations [6]. It has been noted that high resolution images of the breasts with either thallium or Tc-MIBI may demonstrate some normal glandular activity, but this is usually bilateral and non-localizing in character [1,2]. Washout of tracer from both benign and malignant lesions is variable and does not aid in lesion differentiation [6]. Quantification of uptake has also not been of value in differentiating benign from malignant lesions [6]. Tc-MIBI may be superior to Tc-tetrofosmin for the evaluation of breast malignancies based upon in vitro studies [17]. SPECT images provided better lesion contrast, but were more difficult in determining lesion localization [4]. Also, SPECT images often bring out the non-homogeneous characteristics of patients with fibroglandular breasts resulting in an increased risk for a false-positive interpretation [6].

Molecular breast imaging has also been studied as an adjunct to mammography in patients with dense breasts [52]. In one study of patients patients with dense breasts, 14 patients had cancer detected by MIBI imaging alone [52]. However, the addition of MIBI imaging increased the recall rate from 11% to almost 18% and the biopsy rate from 1.3% to 4.2% and two small cancers (less than 5 mm) were not detected scinitgraphically [52]. In patients with newly diagnosed breast cancer, it has been reported that MIBI imaging can detect additional foci of occult breast cancer in 9% of women [59].

It is generally accepted that Tc-MIBI is not accurate in the detection of malignant axillary adenopathy (sensitivity 38-60%) [1,2,19], although sensitivities as high as 79% to 84% have been reported [5,10].

Sestamibi imaging has also been used to monitor response to therapy [47,60]. Residual uptake after therapy is indicative of residual disease [47]. In one study, Sestamibi had a sensitivity of 70% and a specificity of 90% for determining complete response after neoadjuvant chemotherapy (compared to 83% and 60% for MRI, respectively) [60]. Sensitivity of sestamibi was affected by tumor size, with  a sensitivity of 60% for tumors 1 cm or less in size (compared to 77% for MRI) [60].

Radiation dose:

The estimated whole body effective dose is 5 mSv using 600 MBq (16 mCi) of Tc-sestamibi [58] and 8 mSv for a dose of 25 mCi [60]. Using standard doses, the radiation dose is estimated to be 10-20 times higher than that of mammography [53].

However, using a low dose (8 mCi or 296 MBq) exam with a dedicated dual head CZT camera system, the patient's effective dose is decreased to 2 to 2.4 mSv [52,61]. Sestamibi has a propensity to adhere to the plastic walls of syringes, thus decreasing the administered dose by 20-30% and it has been suggested that the actual administered dose is about 6.5 mCi for an effective patient radiation dose of 1.9 mSv [61]. The dose may be further reduced to 4 mCi (148 MBq) for an effective radiation dose of less than 1 mSv [61].

The average effective dose from digital mammography is about 0.5 mSv and the effective dose from mammography with tomosynthesis is 1.2 mSv [52,58], so the MIBI examination dose is approximately twice the dose of a standard 2D mammo with tomosynthesis [61]. However, although the whole-body radiation dose is estimated to be 2 mSv from the MIBI exam (and 0.5 mSv for standard mammography), the actual radiation dose to the breast is orders of magnitude lower than mammography (MIBI is distributed throughout the body, whereas mammo x-rays are directed at the breast [61].

Words of caution: Tc-MIBI is not competitive with mammography on either a cost effective or sensitivity basis for screening patients [6]. All articles regarding Tc-MIBI in the evaluation of breast masses suffer from 2 major drawbacks- 1- The reported results for these studies focuses on a preselected patient population- as a result the incidence of cancer in the patients sent for the exam is usually very high 32-100%. This suggests a selection bias and sensitivity of the exam is likely overestimated [9]. 2- The mean lesion size is generally over 1.0 to 1.5 cm- by this size, a lesion will usually have fairly characteristic mammographic or sonographic findings which can aid in differentiating a benign from a malignant lesion [11]. Furthermore, the cancer detection rate with MIBI is lower than the rate reported for breast MRI in average-risk women with dense breasts (8.8 per 1000 woman screened compared to 15.5 per 1000 woman screened by MRI) ][61]. Other drawbacks include the lack of an adequately high negative predictive value which means malignant lesions may be missed [6,11] and false positive exams occur in benign lesions such as fibroadenomas and inflammatory conditions.

Biopsy remains the  most accurate way to determine whether a lesion is benign or malignant. Stereotactic and ultrasound guided core biopsies of breast lesions are minimally invasive and have a high yield to provide a definite diagnosis. Fine needle biopsies are known to often yield inconclusive results and it is inappropriate to use FNA results as an end point for evaluating the usefulness of scintimammography [43]. Despite optimism in the nuclear medicine literature [43], this exam probably has only a minor role in selected cases for the evaluation of patients with suspected breast malignancy [18]- possibly in patients with palpable masses, but no mammographically detectable abnormality due to dense breasts [31]. However, ultrasound or MRI would still be a better exam to initially evaluate these patients. Unfortunately, almost all of the Tc-MIBI studies have not adequately incorporated breast ultrasound or MRI into the patient management scheme. In fact, contrast enhanced dynamic MR imaging has been shown to have a higher sensitivity than Tc-MIBI - 96% vs 80% [25].

One recent retrospective study focusing on a small number of patients with biopsy proven invasive lobular carcinoma (i.e.: 100% of patients had biopsy proven invasive lobular carcinoma), suggested that the sensitivity of Tc-MIBI (93%) performed on a breast specific gamma camera, was higher than mammography (79%), sonography (68%), and MRI (83%) [45]. Despite the apparent better sensitivity, statistical analysis did not demonstrate a significant difference in detection of invasive lobular carcinoma between the modalities due to the small number of patients included in the study [45]. Also- there is the issue of which technique should be used to biopsy lesions detected only on gamma imaging [45]. None-the-less, there may be a role for gamma imaging in the evaluation of invasive lobular carcinoma- however, larger multicenter, prospective studies will be required to confirm this [45].

For the evaluation of multidrug resistance:

Tumor resistance to chemotherapy is in part mediated through an over-expression of the P-glycoprotein pump and other associated multidrug resistant glycoproteins which are the product of the multidrug resistance gene MDR1 [39]. These glycoproteins are responsible for the outward cellular transport of a variety of chemotherapeutic agents (such an daunorubicin, vincristine, and adriamycin) [33,39]. 99mTc-sestamibi is a substrate for the P-glycoprotein pump and a correlation exists between the efflux rate of 99mTc-sestamibi and the expression of P-glycoprotein in breast cancer [33,39]. By performing early and delayed 99mTc-sestamibi imaging of patients with breast cancer the washout rate of sestamibi can be determined. Lack of significant tracer washout indicates a low risk for chemoresistance [33]. On the other hand, low tracer accumulation and a high washout rate are associated with a high probability for chemoresistance (sensitivity 100%, specificity 80%, and positive predictive value 83%) [33,48]. In these patients, the use of chemo-revertant or chemomodulator agents could be justified [33].

Thyroid Cancer:

Tc-MIBI has also been used in the evaluation of metastatic thyroid cancer. The overall sensitivity of Tc-sestamibi for the detection of thyroid cancer ranges from 36% to 89%, and the specificity is 89-100% [37]. Early imaging (10-30 minutes after tracer administration) will detect more lesions [37]. Sestamibi is particularly sensitive for the detection of nodal metastases [37]. The agent has poor sensitivty for the detection of lung metastases and residual neck bed thyroid tissue [37]. The agent is particularly useful for follow-up of high risk patients with elevated thyroglobulin and negative radioiodine scans, and in patients with hurthle cell or medullary carcinoma. [13,14,27,30]

REFERENCES:
1. J Nucl Med 1995; Maurer AH, et al.  Limitations of craniocaudal thallium-201 and technetium-99m-sestamibi mammoscintigraphy. 36(9):1696-700

2. J Nucl Med 1995; Khalkhali I, et al. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up.36(10):1784-9

3. J Nucl Med 1996; Villanueva-Meyer J, et al. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. 37(6):926-30

4. Radiology 1995; Khalkhali I, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. 196(2):421-6

5. J Nucl Med 1995; Taillefer R, et al. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. 36(10):1758-65.

6. Semin Nucl Med 1997; Waxman AD. The role of Tc-99m-methoxyisobutylisonitrile in imaging breast cancer. 27 (1): 40-54

7. J Nucl Med 1997; Vecchio SD, et al. Fractional retention of Tc-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. 38: 1348-1351

8. J Nucl Med 1997; Kostakoglu L, et al. Clinical validation of the influence of P-glycoprotein on Tc-99m-sestamibi uptake in malignant tumors. 38: 1003-1008

9. J Nucl Med 1997; Tiling R, et al. Comparison of Technetium-99m-sestamibi scintimammography with contrast-enhanced MRI for diagnosis of breast lesions. 38: 58-62

10: J Nucl Med 1998; Taillefer R, et al. Metastatic axillary lymph node technetium-99m-MIBI imaging in primary breast cancer. 39: 459-464

11. J Nucl Med 1999; Prats E, et al. Mammography and Tc-99m-MIBI scintimammography in suspected breast cancer. 40: 296-301

12. J Nucl Med 1999; Khalkhali I, et al. Procedure guideline for breast scintigraphy. 40: 1233-1235

13. J Nucl Med 1998; Miyamoto S, et al. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma. 38: 352-356

14. J Nucl Med 1999; Seabold JE, et al. Comparison of 99mTc-Methoxyisobutyl Isonitrile and 201Tl scintigraphy for the detection of residual thyroid cancer after 131I ablative therapy. 40: 1434-1440

15. Nucl Med Annual 1994; Mountz JM, et al. Brain SPECT: 1994 Update. 1-54 (p.51)

16.  J Nucl Med 1997; Taki J, et al. Evaluating benign and malignant bone and soft tissue lesions with technetium-99m-MIBI scintigraphy. 38: 501-506  

17. J Nucl Med 2000; Rodrigues M, et al. Uptake of 99mTc-MIBI and 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines. 41: 1495-1499

18. Radiol Clin North Am 2000; Pisano ED, et al. Digital mammography, sestamibi breast scintigraphy, and positron emission tomography breast imaging. 38: 861-869

19. J Comput Assist Tomogr 2000; Yutani K, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. 24: 274-280

20. J Nucl Med 2000; Khalkhali I, et al. Diagnostic accuracy of 99m-Tc-Sestamibi breast imaging: Multicenter trial results. 41: 1973-1979

21. J Nucl Med 2001; Buscombe JR, et al. Prediction of the usefulness of combined mammography and scintimammography in suspected primary breast cancer using ROC curves. 42: 3-8

22. J Nucl Med 2001; Pinkas L, et al. 99mTc-MIBI scintigraphy in musculoskeletal tumors. 42: 33-37

23. Radiographics 2001; Polan RL, et al. Scintimammography in patients with minimal mammographic or clinical findings. 21: 641-655

24. Semin Nucl Med 1999; Taillefer R. The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. 29: 16-40

25. Eur J Nucl Med 2001; Imbriaco M, et al. Scintimammography with 99mTc-MIBI versus dynamic MRI for non-invasive characterization of breast masses. 28: 56-63

26. Cancer Research 1990; Delmon-Moingeon LI, et al. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. 50: 2198-2202

27. J Nucl Med 1992; Balon HR, et al. Technetium-99m-sestamibi uptake by recurrent hurthle cell carcinoma of the thyroid. 33: 1393-1395

28. J Nucl Med 1992; Caner B, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: A comparative study with technetium-99m-MDP. 33: 319-324

29. J Nucl Med 1991; Caner B, et al. Increased accumulation of hexakis (2-methoxyisobutylisonitrile) technetium (I) in osteosarcoma and its metastatic lymph nodes. 32: 1977-1978

30. J Nucl Med 1991; O'Driscoll CM, et al. Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylnitrile scintigraphy: A case report. 32: 2281-2283

31. J Nucl Med 2001; Alonso O, et al. Is 99mTc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? 42: 1614-1621

32. Radiology 2001; Khalkhali I, et al. 99mTc Sestamibi breast imaging for the examination of patients with dense and fatty breasts: multicenter study. 222: 149-155

33. J Nucl Med 2002; Sciuto R, et al. Prognostic value of  99mTc Sestamibi washout in predicting response to locally advanced breast cancer to neoadjuvant chemotherapy. 43: 745-751

34. J Nucl Med 2002; Massardo T, et al. Diagnostic value of 99mTc-methylene diphosphonate and 99mTc-pentavalent DMSA compared with 99mTc-sestamibi for palpable breast lesions. 43: 882-888

35. J Nucl Med 2002; Brem RF, et al. High-resolution scintimammography: a pilot study. 43: 909-915

36. J Nucl Med 2002; Piccolo S, Muto P. One step forward. 43: 916-917

37. Endocrine and Metabolism Clinics of North America 2001; Haugen BR, Lin EC. Isotope imaging for metastaic thyroid cancer. 30: 469-492

38. J Nucl Med 2003; Burak Z, et al. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and p-glycoprotein expression. 44: 1394-1401

39. J Nucl Med 2003; Britz-Cunnignham SH, Adelstein SA. Molecular targeting with radionuclides: state of the science. 44: 1945-1961

40. J Nucl Med 2004; Henze M, et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristics analysis. 45: 579-586

41. J Nucl Med 2004; Tiling R, et al. Tissue-specific effects on uptake of 99mTc-sestamibi by breast lesions: a targeted analysis of false scintigraphic diagnoses. 45: 1822-1828

(42) J Nucl Med 2005; Minutoli F, et al. Timing of examination affects reliability of 99mTc-methoxyisobutylisonitrile SPECT in distinguishing neoplastic from nonneoplastic brain hematomas. 46: 574-579

(43) J Nucl Med 2005; Mathieu I, et al. Inconclusive triple diagnosis in breast cancer imaging: is there a role for scintimammography? 46: 1574-1581

(44) Radiology 2008; Brem RF, et al. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. 247: 651-657

(45) AJR 2009; Brem RF, et al. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast specific gamma imaging. 192: 379-383

(46) J Nucl Med 2009; Lee JH, et al. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part I- overview, detection, and staging. 50: 569-581

(47) J Nucl Med 2009; Lee JH, et al. The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2 - response to therapy, other indications, and future directions. 50: 738-748

(48) J Nucl Med 2009; Liu J, et al. Retention of the radiotracers  64Cu-ATSM and  64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. 50: 1332-1339

(49) J Nucl Med 2009; Wagner CC, et al. A pilot study to assess the efficacy of tariquidar to inhibit p-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil PET. 50: 1954-1961

(50) AJR 2014; Rechtman LR, et al. Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. 202: 293-298

(51) AJR 2014; Park JY, et al. Breat-specific gamma imaging correlations with mammographic and clinicopathologic characteristics of breast cancer. 203: 223-228

(52) AJR 2015; Rhodes DJ, et al. Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. 204: 241-251

(53) AJR 2015; Holbrook A, Newell MS. Alternative screening for women with dense breast: breast-specific gamma imaging (molecular breast imaging). 204: 252-256

(54) J Nucl Med 2016: Berg WA. Nuclear breast imaging: clinical results and future directions. 57: 46S-52S

(55) AJR 2017; Hruska CB. Molecular breast imaging for screening in dense breasts: state of the art and future directions. 208: 275-283

(56) AJR 2017; Rauch GM, et al. Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer. 208: 290-299

(57) Radiographics 2017; Shermis RB, et al. Molecular breast imaging in breast cancer screening and problem solving. 37: 1309-1327

(58) AJR 2017; Collarino A, et al. First clinical experience using stereotactic breast biopsy guided by 99mTc-sestamibi. 209: 1367-1373

(59) AJR 2018; Brem RF, et al. Gamma imaging-guided minimally invasive breast biopsy: initial clinical experience. 210: 695-699

(60) AJR 2019; Kim S, et al. Breast-specific gamma imaging versus MRI: comparing the diagnostic performance in assessing treatment response after neoadjuvant chemotherapy in patients with breast cancer. 212: 696-705

(61) AJR 2020; Dibble EH, et al. Molecular breast imaging in clinical practice. 215: 277-284

Page 1 of 6
Next Page